Hyperglycemia associated with targeted oncologic treatment: Mechanisms and management

Oncologist

Volumn 21, Issue 11, 2016, Pages 1326-1336

  Goldman, Jonathan W ^a   Mendenhall, Melody A ^a   Rettinger, Sarah R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Orange County Inc   (United States)

Author keywords

Anticancer agents; Growth factor; Molecular targeted therapy; MTOR protein; Proto oncogene protein akt; Receptors; Tyrosine kinase

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BUPARLISIB; CERITINIB; CIXUTUMUMAB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; INSULIN; IPATASERTIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PILARALISIB; PROTEIN KINASE B; R 1507; RIDAFOROLIMUS; ROCILETINIB; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; UPROSERTIB;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; DIABETES MELLITUS; EXERCISE; FOOD PREFERENCE; HUMAN; HYPERGLYCEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84995480469     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0519     Document Type: Article

References (95)

1. Eurostat. Causes of death statistics-statistics explained. Available at http://ec.europa.eu/eurostat/statistics-explained/index.php/Causes_of_death_statistics#Main_statistical_findings. Accessed July 21, 2015.
2. Heron M. Deaths: Leading causes for 2010. Natl Vital Stat Rep 2013;62:1-96.
3. National Cancer Institute. Targeted cancer therapies fact sheet-National Cancer Institute. Available at http://www.cancer.gov/about-cancer/ treatment/types/targeted-therapies/targeted-therapiesfact-sheet. Accessed July 21, 2015.
4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standardchemotherapy asfirst-linetreatment forEuropeanpatientswithadvancedEGFRmutationpositive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
5. Gridelli C, Ciardiello F, Gallo C et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 2012;30: 3002-3011.
6. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
7. Chen G, Feng J, Zhou C et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2013;24:1615-1622.
8. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3342-3350.
9. Yang JC-H, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUXLung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16: 141-151.
10. Higano CS, Berlin J, Gordon M et al. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMCA12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2015;33:450-462.
11. Schöffski P, Adkins D, Blay JY et al. An openlabel, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013;49:3219-3228.
12. Rajan A, Carter CA, Berman A et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: Amulticentre, open-label, phase 2 trial. Lancet Oncol 2014;15: 191-200.
13. Abou-Alfa GK, Capanu M, O’Reilly EM et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014;60:319-324.
14. Atzori F, Tabernero J, Cervantes A et al. Aphase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17:6304-6312.
15. Reidy-Lagunes DL, Vakiani E, Segal MF et al. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 2012;118:4795-4800.
16. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-5840.
17. Haluska P, Worden F, Olmos D et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-773.
18. Becerra CR, Salazar R, Garcia-CarboneroRet al. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol 2014;73: 695-702.
19. Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
20. Kurzrock R, Patnaik A, Aisner J et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-2465.
21. Pappo AS, Patel SR, Crowley J et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29: 4541-4547.
22. Puzanov I, Lindsay CR, Goff L et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 2015;21:701-711.
23. Jones RL, Kim ES, Nava-Parada P et al. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res 2015;21:693-700.
24. Fassnacht M, Berruti A, Baudin E et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol 2015;16:426-435.
25. Zykadia (ceritinib) capsules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2014.
26. Goyal L, Wadlow RC, Blaszkowsky LS et al. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs 2015;33:128-137.
27. Goldman JW, Raju RN, Gordon GA et al. Afirst in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013;13:152.
28. Socinski MA, Goldman J, El-Hariry I et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068-3077.
29. Jhaveri K, Chandarlapaty S, Lake D et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 2014; 14:154-160.
30. Moore AM, Einhorn LH, Estes D et al. Gefitinib in patients with chemo-sensitive and chemorefractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer 2006;52: 93-97.
31. Wadlow RC, Hezel AF, Abrams TA et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. The Oncologist 2012;17:14.
32. Sequist LV, Goldman JW, Wakelee HA et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive NSCLC patients. J Clin Oncol 2015; 33:8001.
33. Rodon J, Braña I, Siu LL et al. Phase I doseescalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014;32:670-681.
34. Sarker D, Ang JE, Baird R et al. First-in-human phase I study of pictilisib (GDC-0941), a potent panclass I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015;21:77-86.
35. Shapiro GI, Rodon J, Bedell C et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014;20:233-245.
36. Spencer A, Yoon SS, Harrison S J et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood 2014;124:2190-2195.
37. Burris HA, Siu LL, Infante JR et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 2011;29:3003.
38. Tabernero J, Saura C, Roda Perez D et al. Firstin-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive AKT inhibitor GDC-0068. J Clin Oncol 2011;29:3022.
39. Yap TA, Yan L, Patnaik A et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res 2014;20:5672-5685.
40. Ma BB, Goh BC, Lim WT et al. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group(MC1079). Invest New Drugs 2015;33:985-991.
41. Ramanathan RK, McDonough SL, Kennecke HF et al. Phase 2 study of MK-2206, an allosteric inhibitor ofAKT, as second-line therapy foradvanced gastric and gastroesophageal junction cancer: A SWOG Cooperative Group Trial (S1005). Cancer 2015;121:2193-2197.
42. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
43. Oh DY, Kim TW, Park YS et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/ paragangliomas. Cancer 2012;118: 6162-6170.
44. Kamp K, Gumz B, Feelders RA et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Luoctreotate. Endocr Relat Cancer 2013;20:825-831.
45. Amato RJ, Jac J, Giessinger S et al. A phase 2 study with adaily regimenof the oralmTORinhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115: 2438-2446.
46. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
47. Wolpin BM, Hezel AF, Abrams T et al. Oralm TOR inhibitor everolimus in patients with gemcitabinerefractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-198.
48. Milowsky MI, Iyer G, Regazzi AM et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112:462-470.
49. Yoon DH, Ryu MH, Park YS et al. Phase II studyof everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidineandplatinum. Br J Cancer 2012;106:1039-1044.
50. Yoo C, Lee J, Rha SY et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs 2013;31:1602-1608.
51. O’Donnell A, Faivre S, Burris HA III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-1595.
52. Tabernero J, Rojo F, Calvo E et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26: 1603-1610.
53. Yee KW, Zeng Z, Konopleva M et al. Phase I/II studyofthemammaliantarget of rapamycininhibitor everolimus (RAD001) in patients with relapsed or refractoryhematologicmalignancies. Clin CancerRes 2006;12:5165-5173.
54. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011;117:5094-5102.
55. Demetri GD, Chawla SP, Ray-Coquard I et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31:2485-2492.
56. Colombo N, McMeekin DS, Schwartz PE et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. Br J Cancer 2013;108:1021-1026.
57. Oza AM, Pignata S, Poveda A et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015;33:3576-3582.
58. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356: 2271-2281.
59. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22: 909-918.
60. Lamm W, Vogl UM, Bojic M et al. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol 2012;51:101-106.
61. Kruczek K, Ratterman M, Tolzien K et al. Aphase II study evaluating the toxicity and efficacy of singleagenttemsirolimusinchemotherapy-na¨ıvecastrationresistant prostate cancer. Br J Cancer 2013;109: 1711-1716.
62. Armstrong AJ, Shen T, Halabi S et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer 2013;11:397-406.
63. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-1154.
64. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-5304.
65. Reungwetwattana T, Molina JR, Mandrekar SJ et al. Brief report: A phase II “window-of-opportunity” frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 2012;7: 919-922.
66. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-5322.
67. Bendell JC, Kurkjian C, Infante JR et al. Aphase1 studyof the sachet formulation of the oral dual PI3K/ mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs 2015;33:463-471.
68. Makker V, Recio FO, Ma L et al. Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results. J Clin Oncol 2014;32:5513.
69. Britten CD, Adjei AA, Millham R et al. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest New Drugs 2014;32: 510-517.
70. Shapiro GI, Bell-McGuinn KM, Molina JR et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res 2015;21:1888-1895.
71. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl JMed 2015;372:320-330.
72. Keytruda (pembrolizumab) for injection [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2015.
73. Busaidy NL, Farooki A, Dowlati A et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012;30:2919-2928.
74. Guo S. Insulin signaling, resistance, and the metabolic syndrome: Insights from mouse models into disease mechanisms. J Endocrinol 2014;220: T1-T23.
75. Laplante M, Sabatini DM. mTOR signaling in growth controland disease. Cell 2012;149:274-293.
76. Chen HX, Sharon E. IGF-1R as an anti-cancer target-trials and tribulations. Chin J Cancer 2013; 32:242-252.
77. Janssen JA, Varewijck AJ. IGF-IR targeted therapy: Past, present and future. Front Endocrinol (Lausanne) 2014;5:224.
78. Ma H, Zhang T, Shen H et al. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol 2014;77: 917-928.
79. van der Veeken J, Oliveira S, Schiffelers RM et al. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 2009;9:748-760.
80. King ER, Wong KK. Insulin-like growth factor: Current concepts and new developments in cancer therapy. Recent Patents Anticancer Drug Discov 2012;7:14-30.
81. Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 2014;3:360-362.
82. Villadolid J, Ersek JL, Fong MK et al. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res 2015;4:576-583.
83. Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-1709.
84. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic b-cells and a review of the underlying molecular mechanisms. Diabetes 2013;62:2674-2682.
85. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: The second generation of inhibitors. Mol Cancer Ther 2011;10: 395-403.
86. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complexor sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-824.
87. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363: 1801-1811.
88. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-132.
89. Afinitor (everolimus) tablets for oral administration afinitor disperz (everolimus tablets for oral suspension) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2016.
90. Hughes J, Vudattu N, Sznol M et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55-e57.
91. Gaudy C, Clévy C, Monestier S et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015;38:e182-e183.
92. Kochupurakkal NM, Kruger AJ, Tripathi S et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 2014;9:e89561.
93. Vergès B, Walter T, Cariou B. Endocrine side effects of anti-cancer drugs: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 2014;170:R43-R55.
94. Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation studyofBKM120,anoral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-290.
95. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-1685.